Form 4: Coherus BioSciences CFO Granted Stock Options

Coherus BioSciences' Chief Financial Officer, Bryan J. McMichael, was granted stock options for 160,000 shares on January 3, 2025.

Summary

• Bryan J. McMichael, the Chief Financial Officer of Coherus BioSciences, Inc., was granted stock options for 160,000 shares of common stock.
• The options have an exercise price of $1.66 per share.
• The options vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date, January 3, 2025, and the remaining 75% vesting in equal monthly installments over the following three years.
• The options expire on January 3, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative or unusual activity.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of Coherus BioSciences' stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the CFO.

Future Outlook

The stock options will vest over the next four years, subject to the CFO's continued employment with the company.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives.
• The vesting schedule of 4 years with a 1 year cliff is typical for executive stock options.
• The exercise price of $1.66 is dependent on the current share price of CHRS and is not directly comparable to other companies without knowing their share price.

Stakeholder Impact

• The stock option grant may positively impact shareholder value if the company performs well and the stock price increases.
• The grant incentivizes the CFO to work towards the long-term success of the company.

Key Dates

Keywords

stock options, equity compensation, insider trading, CFO, Coherus BioSciences, CHRS